UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

Cardiovascular diabetology, 2020-10, Vol.19 (1), p.176-176, Article 176

2020

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

The journal of clinical endocrinology and metabolism, 2022-06, Vol.107 (7), p.e3003-e3007

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the associations between non-traditional and traditional indices of adiposity and cardiovascular mortality: an observational study of one million person-years of follow-up

International Journal of Obesity, 2019-05, Vol.43 (5), p.1082-1092

2019

Link zum Volltext

Verfügbarkeit prüfen

19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease

Diabetes research and clinical practice, 2022-04, Vol.186, p.109837-109837, Article 109837

2022

Link zum Volltext

Verfügbarkeit prüfen

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial

ESC Heart Failure, 2021-12, Vol.8 (6), p.4517-4527

2021

Link zum Volltext

Verfügbarkeit prüfen

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

Cardiovascular diabetology, 2020-11, Vol.19 (1), p.200-200, Article 200

2020

Link zum Volltext

Verfügbarkeit prüfen

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

ESC Heart Failure, 2020-12, Vol.7 (6), p.3401-3407

2020

Link zum Volltext

Verfügbarkeit prüfen

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial

Journal of the American Heart Association, 2021-04, Vol.10 (7), p.e020053-e020053

2021

Link zum Volltext

Verfügbarkeit prüfen

Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease

ESC Heart Failure, 2024-04, Vol.11 (2), p.737-747

2024

Link zum Volltext

Verfügbarkeit prüfen

Development of a tool to predict the risk of incident heart failure in a general population: the HUNT for HF risk score

ESC Heart Failure, 2023-10, Vol.10 (5), p.2807-2815

2023

Link zum Volltext

Verfügbarkeit prüfen

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome

American journal of preventive cardiology, 2023-09, Vol.15, p.100510, Article 100510

2023

Link zum Volltext

Verfügbarkeit prüfen

Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation

Cardiovascular diabetology, 2019-03, Vol.18 (1), p.26-26, Article 26

2019

Link zum Volltext

Verfügbarkeit prüfen

Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: The randomized controlled Asker and Bærum Cardiovascular Diabetes (ABCD) study

The American heart journal, 2014-09, Vol.168 (3), p.280-288.e2

2014

Link zum Volltext

Verfügbarkeit prüfen

Myocardial dysfunction and cardiovascular disease in type 2 diabetes

Scandinavian journal of clinical and laboratory investigation, 2016-05, Vol.76 (4), p.271-281

Ofstad, Anne Pernille

2016

Link zum Volltext

Verfügbarkeit prüfen

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

The Lancet (British edition), 2020-09, Vol.396 (10254), p.819-829

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

Circulation (New York, N.Y.), 2021-01, Vol.143 (4), p.337-349

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial

European journal of heart failure, 2020-01, Vol.22 (1), p.126-135

2020

Link zum Volltext

Verfügbarkeit prüfen

The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions

Heart failure reviews, 2018-05, Vol.23 (3), p.303-323

2018

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure

Journal of the American College of Cardiology, 2021-09, Vol.78 (13), p.1337-1348

2021

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

Circulation (New York, N.Y.), 2022-08, Vol.146 (9), p.676-686

2022

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality: Insights From the EMPA-REG OUTCOME Trial

Circulation (New York, N.Y.), 2019-03, Vol.139 (11), p.1458-1460

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes

Diabetes, obesity & metabolism, 2022-06, Vol.24 (6), p.1061-1071

2022

Link zum Volltext

Verfügbarkeit prüfen

Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk

Journal of diabetes and its complications, 2023-11, Vol.37 (11), p.108628-108628, Article 108628

2023

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality

Circulation (New York, N.Y.), 2019-03, Vol.139 (11), p.1458-1460

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(70)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(43)
Science & Technology
(43)
Humans
(33)
Cardiovascular System & Cardiology
(28)
Cardiac & Cardiovascular Systems
(26)
Diabetes
(26)
Cardiovascular Disease
(22)
Diabetes Mellitus
(22)
Heart Failure
(22)
Mortality
(22)
Risk Factors
(22)
Empagliflozin
(20)
Endocrinology & Metabolism
(17)
Type 2 Diabetes
(17)
Cardiovascular Diseases
(16)
Diabetes Mellitus, Type 2 - Complications
(16)
Diabetes Mellitus, Type 2 - Drug Therapy
(16)
Female
(14)
Male
(13)
Treatment Outcome
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

Comparison of the associations between non-traditional and traditional indices of adiposity and cardiovascular mortality: an observational study of one million person-years of follow-up

19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME

Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial

Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease

Development of a tool to predict the risk of incident heart failure in a general population: the HUNT for HF risk score

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome

Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation

Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: The randomized controlled Asker and Bærum Cardiovascular Diabetes (ABCD) study

Myocardial dysfunction and cardiovascular disease in type 2 diabetes

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial

The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions

Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality: Insights From the EMPA-REG OUTCOME Trial

Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes

Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality

Suchergebnisse filtern